Merck & Co Inc. (MRK) on Friday said its Keytruda in combination with fluoropyrimidine- and platinum-containing-chemotherapy has been approved by Health Canada for the treatment of gastric or gastroesophageal junction (GEJ) adenocarcinoma in adults. This approval is based on results from the Phase 3 KEYNOTE-859 trial, in which treatment with Keytruda plus chemotherapy showed statistically significant improvement in overall survival (OS), progression-free survival (PFS) and objective response rate (ORR) compared to placebo in combination with chemotherapy in patients with gastric cancers.Keytruda was first approved in 2014 by the US FDA to treat advanced or unresectable melanoma.

默克公司（Merck＆Co Inc.）周五表示，其Keytruda联合含氟嘧啶和铂的化疗已被加拿大卫生部批准用于治疗成人胃或胃食管交界处（GEJ）腺癌。这项批准是基于KEYNOTE-859期临床试验的结果，在该试验中，与安慰剂联合化疗治疗胃癌患者相比，Keytruda联合化疗治疗显示总生存期（OS），无进展生存期（PFS）和客观缓解率（ORR）有统计学显着改善。2014年，美国FDA首次批准Keytruda治疗晚期或不可切除的黑色素瘤。

It is currently approved for several indications including advanced renal cell carcinoma, bladder cancer, non-small cell lung carcinoma, cervical cancer, among others. For comments and feedback contact: editorial@rttnews.comBusiness News.

目前已被批准用于多种适应症，包括晚期肾细胞癌，膀胱癌，非小细胞肺癌，宫颈癌等。如需评论和反馈，请联系：editorial@rttnews.comBusiness新闻。